VivoSeq
Neurology

Secondary Progressive Multiple Sclerosis

45

Pipeline Programs↗

11

Active Trials↗

22

Companies Involved↗

Secondary Progressive Multiple Sclerosis is a moderately active landscape with 45 programs across 22 companies. The most active players are Roche, Kyverna Therapeutics, Innate Immunotherapeutics. 8 therapies are approved with 18 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

19/100

Mech. Concentration

11/100

Completion Rate

65/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 1K

Kyverna Therapeutics

3 programs

Phase 2I

Innate Immunotherapeutics

1 program

Phase 2O

Opexa Therapeutics, Inc.

1 program

Phase 2G

Glaxo Dba Glaxosmithkline

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

33 of 44 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody511%Cell therapy37%Protein / enzyme12%Peptide12%RNA therapy12%

Small molecule leads; the ring shows all 44 classified programs, each share of the total. Modality classified for 98% of 50 pipeline programs.

Analysis

Trial Status

36

clinical trials

Completed15 · 42%
Recruiting7 · 19%
Terminated6 · 17%
Active, not recruiting3 · 8%
Withdrawn2 · 6%
No longer available1 · 3%
Other2 · 6%

Clinical Trials

Trial Activity

36 trials

The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis
Recruiting·—·Phase 2·NCT06599307·46 enrolled
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Recruiting·Sanofi logoSanofi·Phase 3·NCT06141486·900 enrolled
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Recruiting·TTiziana Life Sciences LTD·Phase 2·NCT06890923·55 enrolled
Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)
Recruiting·RRennes University Hospital·Phase 3·NCT03653273·250 enrolled
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Recruiting·TTr1X, Inc.·Phase 1/2·NCT07477639·39 enrolled
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Remibrutinib in Patients With Secondary Progressive Multiple Sclerosis
Recruiting·Novartis logoNovartis·Phase 3·NCT07225504·1,275 enrolled
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-active Secondary Progressive Multiple Sclerosis
Recruiting·ZZenas BioPharma (USA), LLC·Phase 3·NCT07299019·990 enrolled
Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis
Active, not recruiting·AAB Science·Phase 3·NCT05441488·800 enrolled
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
Active, not recruiting·KKyverna Therapeutics·Phase 2·NCT06384976·120 enrolled
A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Active, not recruiting·TTiziana Life Sciences LTD·Phase 2·NCT06292923·54 enrolled
Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis
Not yet recruiting·NNeuroGenesis Ltd.·Phase 2·NCT06961383·45 enrolled
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Completed·Novartis logoNovartis·Phase 3·NCT01665144·1,651 enrolled
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
Completed·Novartis logoNovartis·Phase 4·NCT04792567·41 enrolled
Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis
Completed·IInnate Immunotherapeutics·Phase 2·NCT02228213·93 enrolled
Domperidone in Secondary Progressive Multiple Sclerosis (SPMS)
Completed·UUniversity of Calgary·Phase 2·NCT02308137·64 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)